Tumor mutational burden shapes success and resistance in cancer immunotherapy
Aguade-Gorgorio, G.
Show abstract
Immunotherapy, particularly immune checkpoint blockade, has transformed cancer treatment, yet durable responses remain limited to a subset of patients and cancer types. Many tumors exhibit innate resistance or acquire resistance through immune evasion or neoantigen editing. A central factor in shaping these outcomes is the tumor mutational burden. However, cancer mutations can enhance or impair both cellular replication and immune recognition, reflecting the non-trivial role of mutational load in immunotherapy success and failure. Here, we present a minimal eco-evolutionary model that captures trade-offs between oncogenic and immunogenic mutations in cancer cell replication. Despite its simplicity, the model reveals a rich phase space, including an evolutionary bistable regime where both immunologically silent and mutationally active tumor strategies can coexist. Notably, the model explains two key eco-evolutionary mechanisms of resistance to immunotherapy: preexisting resistance, driven by the persistence of silent clones within genetically unstable tumors; and immunoediting, where immune pressure selects for reduced antigenicity over time.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.